Products > Tibella

Tibella® (tibolone) is an innovative product for short-term treatment of vasomotor symptoms due to estrogen deficiency in postmenopausal women, more than one year after menopause. Tibella® is different from other Hormone Replacement Therapies (“HRTs”), as it does not contain actual hormones. Instead, the body breaks down tibolone to make three substances that act like estrogen, progesterone, and androgen. These substances act on different tissues in the body to help treat symptoms of menopause. Tibella® substitutes for the loss of estrogen production in postmenopausal women and alleviates menopausal symptoms, such as hot flushes and sweating episodes.

Tibella® has been succesfully used by healthcare professionals worldwide for over 30 years and is now available in Canada.

Menopause can occur after the age of 45 for most women. Approximately 60% to 80% of women will experience vasomotor symptoms of menopause. In Canada, almost 4 million women between the ages of 45 and 59, have gone through or will soon go through menopause. Up to 80% or women may suffer from at least one menopausal symptom including mood swings, irritability, interrupted sleep, hot flushes or vaginal dryness.

Tibella – Now Available


TIBELLA Product Monograph, BioSyent Pharma Inc. May 2019

The Society of Obstetricians and Gynaecologists of Canada

Canadian Menopause Society.

  Print Page | Page Top
Annual Report  
Information Circular  
Company Financials  
Corporate Fact Sheet  
Latest Press Release  
CEO Interview  
Current Stock Quote:
Contact Information
2476 Argentia Road, Suite 402   T: 905.206.0013
Mississauga, Ontario, Canada   F: 905.206.1413
L5N 6M1   E:
Connect with BioSyent
Copyright 2019 BioSyent Inc.